Cellectis是一家以巴黎为基础的生物技术开发基因编辑的癌症治疗方案, 获得“Moderate Buy”评级, 平均目标为6.33美元, 平均12个月。 Cellectis, a Paris-based biotech developing gene-edited cancer therapies, received a "Moderate Buy" rating with a $6.33 average 12-month target.

Cellectis(CLLS)获得了5个经纪人的“机动购买”共识评级,平均12个月价格目标为6.33美元。 Cellectis (CLLS) received a "Moderate Buy" consensus rating from five brokers, with an average 12-month price target of $6.33. Jefferies以“买入”评级和7.00美元的目标开始报导, Jefferies initiated coverage with a "buy" rating and $7.00 target, citing potential upside. 股票以3.73美元开放,过去一年交易额在1.10美元至5.48美元之间。 The stock opened at $3.73, trading between $1.10 and $5.48 over the past year. 以美国为基地的巴黎生物技术公司使用其TALEN平台开发经基因编辑的血癌和固态肿瘤CAR-T疗法。 The biotech firm, based in Paris with U.S. operations, develops gene-edited CAR-T therapies for blood cancers and solid tumors using its TALEN platform. 财务显示,债务与股本比率为0.63,现期/短期比率为1.49,表明流动性稳定。 Financials show a debt-to-equity ratio of 0.63 and current/quick ratios of 1.49, indicating stable liquidity. 大约63.9%的股票由短卖方持有。 About 63.9% of shares are held by short sellers.